Шрифт:
Закладка:
7805
de Groot S, Lugtenberg RT, Cohen D, et al. Fasting mimicking diet as an adjunct to¿neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020;11(1):3083. https://pubmed.ncbi.nlm.nih.gov/32576828/
7806
Vernieri C, Ligorio F, Zattarin E, Rivoltini L, de Braud F. Fasting-mimicking diet plus chemotherapy in breast cancer treatment. Nat Commun. 2020;11(1):4274. https://pubmed.ncbi.nlm.nih.gov/32848145/
7807
Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011;30(30):3305–16. https://pubmed.ncbi.nlm.nih.gov/21516129/
7808
Lee C, Safdie FM, Raffaghello L, et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70(4):1564–72. https://pubmed.ncbi.nlm.nih.gov/20145127/
7809
Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4(124):124ra27. https://pubmed.ncbi.nlm.nih.gov/22323820/
7810
Longo VD, Lieber MR, Vijg J. Turning anti-ageing genes against cancer. Nat Rev Mol Cell Biol. 2008;9(11):903–10. https://pubmed.ncbi.nlm.nih.gov/18946478/
7811
Clemmons DR, Klibanski A, Underwood LE, et al. Reduction of plasma immunoreactive somatomedin C during fasting in humans. J Clin Endocrinol Metab. 1981;53(6):1247–50. https://pubmed.ncbi.nlm.nih.gov/7197688/
7812
Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008;7(5):681–7. https://pubmed.ncbi.nlm.nih.gov/18843793/
7813
Kazemi A, Speakman JR, Soltani S, Djafarian K. Effect of calorie restriction or protein intake on circulating levels of insulin like growth factor I in humans: a systematic review and meta-analysis. Clin Nutr. 2020;39(6):1705–16. https://pubmed.ncbi.nlm.nih.gov/31431306/
7814
Fontana L, Villareal DT, Das SK, et al. Effects of 2-year calorie restriction on circulating levels of IGF-1, IGF-binding proteins and cortisol in nonobese men and women: a randomized clinical trial. Aging Cell. 2016;15(1):22–7. https://pubmed.ncbi.nlm.nih.gov/26443692/
7815
Most J, Tosti V, Redman LM, Fontana L. Calorie restriction in humans: an update. Ageing Res Rev. 2017;39:36–45. https://pubmed.ncbi.nlm.nih.gov/27544442/
7816
Kazemi A, Speakman JR, Soltani S, Djafarian K. Effect of calorie restriction or protein intake on circulating levels of insulin like growth factor I in humans: a systematic review and meta-analysis. Clin Nutr. 2020;39(6):1705–16. https://pubmed.ncbi.nlm.nih.gov/31431306/
7817
Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008;7(5):681–7. https://pubmed.ncbi.nlm.nih.gov/18843793/
7818
Solon-Biet SM, Mitchell SJ, de Cabo R, Raubenheimer D, Le Couteur DG, Simpson SJ. Macronutrients and caloric intake in health and longevity. J Endocrinol. 2015;226(1):R17–28. https://pubmed.ncbi.nlm.nih.gov/26021555/
7819
Piper MDW, Partridge L, Raubenheimer D, Simpson SJ. Dietary restriction and ageing: a unifying perspective. Cell Metab. 2011;14(2):154–60. https://pubmed.ncbi.nlm.nih.gov/21803286/
7820
Pamplona R, Barja G. Mitochondrial oxidative stress, aging and caloric restriction: the protein and methionine connection. Biochim Biophys Acta. 2006;1757(5–6):496–508. https://pubmed.ncbi.nlm.nih.gov/16574059/
7821
Speakman JR, Mitchell SE, Mazidi M. Calories or protein? The effect of dietary restriction on lifespan in rodents is explained by calories alone. Exp Gerontol. 2016;86:28–38. https://pubmed.ncbi.nlm.nih.gov/27006163/
7822
Solon-Biet SM, McMahon AC, Ballard JWO, et al. The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and longevity in ad libitum-fed mice. Cell Metab. 2014;19(3):418–30 https://pubmed.ncbi.nlm.nih.gov/24606899/
7823
Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492(1):203–6. https://pubmed.ncbi.nlm.nih.gov/10858549/
7824
McCarty MF. Practical prospects for boosting hepatic production of the “pro-longevity” hormone FGF21. Horm Mol Biol Clin Investig. 2017;30(2). https://pubmed.ncbi.nlm.nih.gov/26741352/
7825
Andersen B, Straarup EM, Heppner KM, et al. FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys. Int J Obes (Lond). 2018;42(6):1151–60. https://pubmed.ncbi.nlm.nih.gov/29892039/
7826
Zhang Y, Xie Y, Berglund ED, et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife. 2012;1:e00065. https://pubmed.ncbi.nlm.nih.gov/23066506/
7827
Solon-Biet SM, Mitchell SJ, de Cabo R, Raubenheimer D, Le Couteur DG, Simpson SJ. Macronutrients and caloric intake in health and longevity. J Endocrinol. 2015;226(1):R17–28. https://pubmed.ncbi.nlm.nih.gov/26021555/
7828
Lee MB, Hill CM, Bitto A, Kaeberlein M. Antiaging diets: Separating fact from fiction. Science. 2021;374(6570):eabe7365. https://pubmed.ncbi.nlm.nih.gov/34793210/
7829
Riera CE, Dillin A. Can aging be ‘drugged’?. Nat Med. 2015;21(12):1400–5. https://pubmed.ncbi.nlm.nih.gov/26646496/
7830
Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep. 2017;19(4):28. https://pubmed.ncbi.nlm.nih.gov/28337713/
7831
Pérez-Martí A, Sandoval V, Marrero PF, Haro D, Relat J. Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds. Horm Mol Biol Clin Investig. 2016;30(1). https://pubmed.ncbi.nlm.nih.gov/27583468/
7832
Sonoda J, Chen MZ, Baruch A. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig. 2017;30(2). https://pubmed.ncbi.nlm.nih.gov/28525362/
7833
Talukdar S, Zhou Y, Li D, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016;23(3):427–40. https://pubmed.ncbi.nlm.nih.gov/26959184/
7834
Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27(7):1262–71. https://pubmed.ncbi.nlm.nih.gov/34239138/
7835
Jimenez V, Jambrina C, Casana E, et al. FGF21 gene therapy as treatment for obesity and insulin resistance.
